Related Experiment Video
Updated: Mar 30, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
28.0K
Bevacizumab for recurrent primary central nervous system lymphoma: a new treatment?
Karina Nieto1, Leo I Gordon1, Jeffrey Raizer1
1Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois (K.N., J.R.); Department of Medicine (Hematology/Oncology), Northwestern University, Feinberg School of Medicine, Chicago, Illinois (L.I.G., J.R.); Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois (L.I.G., J.R.).
Neuro-Oncology
|November 7, 2015
Abstract
No abstract available in PubMed .
Related Concept Videos
02:56Treatment Resistent Cancers
1.5K
1.5K
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
01:27Tumor Immunotherapy
2.2K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K